Abstract: A topical antibacterial preparation for treating infected wounds and for advancing their healing comprises silver sulfadiazine (SSD) and collagen, in which the w/w ratio of collagen to SSD ranges from 4/1 to 200/1. The concentration of the SSD is preferably from 0.5% to 2.5%, advantageously 1%. The collagen is advantageously native collagen, which may be acid soluble or insoluble, or mixtures thereof. The preparation may comprise an inert excipient, e.g. SiO.sub.2, or blood plasma components, peptides, carbohydrates.

Abstract: Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl andR.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl; are provided.

Abstract: N-acyl-derivatives of hydroxyamines suitable for the therapeutic treatment of pathologies characterized by degranulation of mast cells caused by a neurogenic and/or immunogenic hyperstimulation.

Abstract: A method of alleviating pain such as neuropathic pain or acute inflammatory pain is provided which comprises administering to a mammal that is either exhibiting pain or is about to be subjected to a pain-causing event a pain alleviating/pain suppressing amount of at least one nontoxic antagonist for the N-methyl-D-aspartate receptor, e.g., dextrorphan, or metabolic precursor of such antagonist, e.g., dextromethorphan, or at least one nontoxic substance that blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation, e.g., a phenothiazine such as trifluoperazine.

Abstract: Novel glycosides 7-ketosteryl di-O-acyl-pyranoside and 7-.beta.-hydroxycholesteryl 2,3-dideoxy-.alpha.-D-erythro-hex-2-enopyranoside. The glycosides possess valuable pharmacological properties as a medicament. In particular, the cholesterol glycoside in vivo exhibits a selective cell-destructive activity on malignant cells which activity is substantially free of side effects on normal cells. The glycosides possess useful properties, especially pharmacological properties which are the same as the respective unglycosylated aglycon.

Abstract: A topical preparation of between 1% and 3% hydrocortisone and 1.5% and 4.5% tolnaftate, by weight, in a 2:3 ratio used for treating a fungal infection of the skin. The specified ratio provides an accelerated and non-toxic treatment.

Abstract: A method of treating degenerative musculoskeletal diseases such as rheumatoid arthritis and osteoaarthritis in an animal, typically a human, comprises administering to the animal, typically enterally, in a convenient dosage form, a therapeutically effective amount of the beneficiated extracts of the plants ASHWAGANDHA (Withania somnifera), SALLAI GUGGUL (Boswellia serrata), TURMERIC (Curcuma longa), and GINGER (Zingiber officinale) in a predetermined proportion relative to each other with or without other biologically active inorganic ingredients, such as zinc sulphate. The beneficiated plant extracts are made in accordance with a novel process which is also disclosed.

Abstract: Methods of using shulL-1Rs to suppress IL-1 mediated inflammation in a mammal.

Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.

Abstract: A method for reducing the inflammatory response in tissue of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.

Abstract: A biologically persistent, water-soluble, substantially non-immunogenic, substantially non-antigenic conjugate of superoxide dismutase is prepared by coupling one to five strands of a polyalkylene glycol which is polyethylene glycol or polyethylene-polypropylene glycol copolymer, wherein said polyalkylene glycol has an average molecular weight of about 35,000-1,000,000.

Abstract: Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl andR.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl;are provided.

Abstract: Autoimmune diseases are controlled by the administration of non-methylene interrupted fatty acids of the formula ##STR1## in which R is alkyl or alkenyl. A preferred compound within the scope of this formula is 5,11,14-eicosatrienoic acid.

Abstract: Dermatological compositions having an effective content of cis-urocaninic acid and/or its derivatives, the process for the produktion of such compositions and the method of use of dermatological compositions having a content of cis-urocaninic acid for the treatment and the prophylaxis of inflammatory dermatoses and for the care and restoration of senstive and stressed skin.

Abstract: An improved plasmid for the production of superoxide dismutase on an analog thereof which upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a gene encoding superoxide dismutase or the analog. The plasmid is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon; a second restriction enzyme site; a gene encoding superoxide dismutase or the analog; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the plasmid is present in the host. The distance between the 3' end of P.sub.L O.sub.L and the 5' end of the N utilization site is less than about 80 base pairs.

Abstract: A novel polypeptide [Ala IL-8].sub.77 is provided which is a potent modulator of neutrophil functions. The polypeptide factor and related compositions find use as anti-inflammatory agents and as therapeutics for clinical indications in which damage to vascular endothelium and other tissues occurs. The amino acid and nucleotide sequence of the factor and methods for its purification, recombinant production and pharmaceutical use are provided.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is hydrogen or (C.sub.1 -C.sub.6)alkyl; R.sup.2 is phenyl, pyridyl, thienyl or furyl, and R.sup.2 may optionally be substituted with from one to three substituents independently selected from (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, chloro, fluoro, bromo, iodo, and trifluoromethyl; R.sup.3 is phenyl, naphthyl, pyridyl, thienyl or furyl, and R.sup.3 may optionally be substituted with from one to three substituents independently selected from (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, chloro, fluoro, bromo, iodo and trifluoromethyl; and the pharmaceutically acceptable salts of such compounds.These compounds are substance P antagonists and useful in the treatment of gastrointestinal disorders, inflammatory disorders, central nervous system disorders and pain.

Abstract: A method of treating an inflammatory disease in a mammal, e.g., a human, by inhibiting pro-inflammatory mediator release from basophils or mast cells in the human, by administering to the human a therapeutically effective amount of purified or recombinant platelet factor 4 (PF4), a PF4 analog, or a peptide fragment of PF4 or the analog.

Abstract: A topical agent and method for the treatment and prevention of pseudofolliculitis barbae, related secondary bacterial infections and other skin conditions associated with shaving result from a combination of three ingredients, namely benzoyl peroxide, camphor oil and aloe vera present in 15:4:1 parts by volume of the composition, respectively.

Abstract: 1-Ether and 1-thioether-naphthalene-2-carboxamides are described, methods of manufacture therefor and their use as agents which inhibit leukocyte adherence to vascular endothelium and, as such, are effective therapeutic agents for treating inflammatory diseases, and their utility in inhibiting the activation of human immunodeficiency virus (HIV), latent in infected humans.

Abstract: The present invention relates to new polycyclic aromatic derivatives, to processes for their preparation and to their use in therapeutic and cosmetic formulations.

Abstract: An antifungal agent for the treatment of skin disease such as athlete's foot, ringworm and tinea caused by dermatophytes, eczema, tinea or various fungi, which comprises a 100 weight % of detergent solution including 0.01-40 weight % of sodium hypochlorite, 0.01-30 weight % of sodium sulfite, 0.01-40 weight % of sodium nitrite, 0.01-40 weight % of sodium chlorate, 0.01-40 weight % of potassium chlorate, 0.001-35 weight % of hydrogen peroxide, 0.01-40 weight % of ozone water, 0.01-40 weight % of sodium nitrite, 0.01-40 weight % of potassium nitrite, 0.001-1 weight % of nonionic surface active agent and 1-90 weight % of water.It is characterized in that trichophyton, eczema or various fungi in the dermis or deep layer are allured by oxygen contained in the antifungal agent to or near the surface of the skin for easy sterilization by oxidation, reduction, bleaching and fungicidal activity.A ligand agent is also efficacious for the treatment of a burn of the skin and of stiffness in the shoulder.

Abstract: Methods of treatment of the human or animal body are provided to combat conditions responsive to lithium and/or C.sub.18-22 polyunsaturated fatty acid therapy, including conditions associated with essential lithium deficiency, and also transfer of lipid-enveloped viruses between humans or animals or between cells within a human or animal body. The methods include administration of an effective amount of a lithium salt of a C.sub.18-22 polyunsaturated fatty acid. Devices for combatting transmission of viral diseases including lithium salts of a C.sub.18-22 polyunsaturated fatty acid are also provided.

Abstract: Solution comprising a mixture of aluminum acetate topical solution and glycerin useful as a skin moisturizer and/or a food particulate repellant for preventing chewed food particles from sticking to the teeth. When combined with a flavoring agent, the solution of aluminum acetate topical solution and glycerin is also effective as a saliva substitute for relieving the symptoms of xerostomia or "dry mouth syndrome.

Abstract: Dehydroepiandrosterone (DHEA) has an immune response regulating effect in vertebrates to protect from morbid effect of infection and immune suppressive therapies. DHEA is also effective for use in treatment of alopecia. Protection results from a generalized host response.

Abstract: The invention concerns a heterocyclic derivative of the formula I, ##STR1## wherein Ar.sup.1 is optionally substituted phenyl or naphthyl;A.sup.1 is (1-6C)alkylene, (1-6C)alkenylene, (3-6C)alkynylene or cyclo-(3-6C)alkylene;Ar.sup.2 is optionally substituted phenylene;R.sup.1 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; andR.sup.2 and R.sup.3 together form a group of the formula --A.sup.2 --X--A.sup.3 -- which, together with the carbon atom to which A.sup.2 and A.sup.3 are attached, defines a ring having 7 ring atoms, wherein A.sup.2 and A.sup.3 is (1-4C)alkylene and X is oxy;or a pharmaceutically-acceptable salt thereof.These compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

Abstract: The invention relates to the use of preparations of the plant Curcuma longa or other curcumin-containing plants, curcumin or curcumin derivatives for the prophylaxis and/or treatment of conditions associated with excessive formation of leucotrienes and/or prostaglandins and to the use of preparations of the plant Curcuma longa or other curcumin-containing plants, curcumin or curcumin derivatives for the production of medicaments for the prophylaxis and/or treatment of conditions associated with excessive formation of leucotrienes and/or prostaglandins.

Abstract: The present invention features saponin containing enteral formulations for treatment of infection and inflammation. These saponin containing formulations are particularly useful in conjunction with oils rich in .omega.3 polyunsaturated fatty acids such as fish oils and flax oil but also show benefits with .omega.6 rich oils such as borage oil, black currant seed oil, canola oil and rapeseed oil. These formulations may also contain a lignan from the sesamin family.

Abstract: A class of substituted spiro compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula III: ##STR1## wherein n is a number selected from 0, 1 and 2; wherein R.sup.3 is methylsulfonyl or sulfamyl; and wherein R.sup.8 is selected from hydrido, fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, hydroxyl, mercapto, methylthio, ethylthio, cyano, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, trifluoromethoxy, hydroxymethyl, methoxymethyl and ethoxymethyl; or a pharmaceutically-acceptable salt thereof.

Abstract: Pharmaceutical preparations for the treatment of hyperproliferative epidermal conditions comprising the specific negative growth factor activin A, and their use in methods of treatment of hyperproliferative epidermal conditions.

Abstract: The present invention provides a method for inhibiting viral proliferation by preventing or inhibiting viral replication or killing the viruses on contact. Viral replication is prevented or inhibited through the use of serine protease inhibitors, their analogs, salts, conjugates or derivatives.

Abstract: A liquid pharmaceutical composition which can be administered as a foam by means of suitable supplying devices, without necessity of gas propeller, said composition consisting of:a) one or more natural or synthetic ionic or non ionic, acid, basic or neutral surfactants;b) a solvent or a solvent mixture;c) an active ingredient or a combination of active ingredients;d) optionally mucoadhesive or thermosetting polymers;e) optional adjuvants or excipients.

Abstract: A novel class of pharmaceutically active boronated compounds are provided. The boronated compounds include boronated purine and pyrimidine bases and boronated nucleosides, as well as phosphate esters and oligomers thereof. The compounds are boronated at the ring nitrogen of the purine or pyrimidine base, or at a 2', 3' or 5' amino substituent of the nucleoside sugar.

Abstract: A method of and composition for concentrating a therapeutic agent in an inflamed dermal region are disclosed. The composition, which is also used in the method, is a liposomal composition. The liposomes contain the therapeutic agent in entrapped form and are composed of vesicle-forming lipids including a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer. After intravenous administration, the liposomes are taken up by the inflamed region within 24-48 hours, for site-specific release of entrapped compound into the inflamed region.

Abstract: New substituted cyclopropylamino-1,3,5-triazines having the formula ##STR1## wherein R.sub.1 is C.sub.1 -C.sub.3 -alkyl, C.sub.3 -C.sub.5 -cycloalkyl or C.sub.1 -C.sub.3 -alkyl-C.sub.3 -C.sub.5 -cycloalkylR.sub.2 is bis(2-hydroxyethyl)amino, 3-hydroxy-1-azetidinyl, 3-methoxy-1-azetidinyl, 3-oxo-1-azetidinyl, morpholino, 4-hydroxypiperidino, thiomorpholino, thiomorpholino S-oxide, thiomorpholino S,S-dioxide, 3-thiazolidinyl, 3-thiazolidinyl S-oxide, 3-thiazolidinyl S,S-dioxide or 8-oxa-3-azabicyclo[3,2,1]oct-3-yl. Processes for the preparation thereof and pharmaceutical composition containing them are also given. The compounds are useful for the treatment of inflammation and asthma.

Abstract: The present invention is directed to a method for testing the susceptibility of a mammal to inflammatory diseases which comprises the steps of:administering to a mammal a compound selected from the group consisting of Type 1 mineralocorticoid receptor antagonists, opiate antagonists, estrogen antagonists or mixed estrogen agonists/antagonists, progesterone agonists; or a combination of an estrogen antagonist with one or a combination of a Type I glucocorticoid receptor antagonist, a Type II glucocorticoid agonist or a progesterone agonist which is effective in stimulating the hypothalamic-pituitary-adrenal (HPA) axis; andmeasuring the level of at least one hormone secreted by the hypothalamus, pituitary or adrenal glands of said mammal.The present invention is also directed to methods of treating inflammatory diseases.

Abstract: Interleukin-1.beta. (IL-1.beta.) and derivatives, and their pharmaceutical compositions for use in treating arthritis or inflammation.

Abstract: Interleukin-1.alpha. (IL-1-.alpha.) and derivatives, and their pharmaceutical compositions for use in treating arthritis or inflammation.

Abstract: The protein fraction from Leguminosae seeds, which is characterized by at least one band in polyacrylamide gel electrophoresis with sodium dodecyl sulfate, by relative molecular masses from 3,000 to 30,000 g/mole, by a content of total nitrogen of 14 to 20% and amino nitrogen of 1 to 2% related to the protein content and by further parameters defined in claim 1, is appropriate for the care of skin and for the treatment of inflammatory skin diseases, whereby the protein fraction is generally used as a concentrate of active substances or e.g. as a cream, lotion, emulsion, gel, face mask, powder or plaster.

Abstract: Disclosed is water-soluble composition made by subjecting pentacyclic triterpene compound belonging to amylin group such as oleanolic acid, ursolic acid and hederagenin to inclusion in cyclodextrins. Though the aforementioned pentacyclic triterpene compound has various pharmacological functions, it has suffered a disadvantage such that it is insoluble in water. However, by subjecting the compound to inclusion in cyclodextrins, the water-soluble composition can be made with maintaining the pharmacological functions, and applied for foods, drinks, toothpaste, gargle and chewing gum, exhibiting the effect of cariostatic.

Abstract: A pharmaceutcial composition is provided for use in the prevention or treatment of viral infections caused by enveloped viruses. The composition comprises a fibroblast growth factor, a sulfated polysaccharide with antiviral activity, and one or more pharmaceutically acceptable carriers. The fibroblast growth factor may be a basic fibroblast growth factor or an analogue thereof, and the polysaccharide may be a carrageenan, heparin, dextran sulfate, pentosan polysulfate or a sulfated polysaccharides produced by marine algae belonging to the class of Rhodophyceae.

Abstract: The new compositions of the invention are formed by the total acid fraction obtained by alkali hydrolysis of the lipid extracts of the fruit of Sabal serrulata. Said compositions have an effective adrenergic antagonist action and a complementary antiinflammatory action, together with a high degree of innocuity and slight side effects, making its use highly effective for combatting prostate affections and, more particularly, benign hypertrophy of the prostate.

Abstract: Hydroxy-substituted [(D)Ser].sup.8 -Ciclosporin derivatives, particularly [O-(2-hydroxyethyl)(D)Ser].sup.8 -Ciclosporin, have advantageous pharmacological properties and are useful as immunosuppressants, for example in the treatment of transplant rejection and autoimmune diseases.

Abstract: The invention provides compounds of the general formula (I) ##STR1## or a physiologically acceptable salt or solvate thereof, wherein Q represents a 1- or 2-naphthalenyl group.The compounds have a stimulant action at .beta..sub.2 -adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R is hydrogen, lower alkyl or phenyl;R.sup.1 is hydrogen, lower alkyl, phenyl, halo, hydroxy, lower alkoxy or trifluoromethyl;R.sup.2 is phenyl, phenylloweralkyl, thienyl, furyl, pyrrolyl, pyridyl, benzothienyl, benzofuryl, indolyl, quinolinyl, or any of the foregoing substituted with halo, lower alkyl, lower alkylcarbonyl, benzoyl, carboxy, lower alkoxycarbonyl, OR.sup.3, N(R.sup.3).sub.2, CON(R.sup.3).sub.2, phenylsulfonyl, lower alkylsulfonyl, cyano, nitro or trifluoromethyl;R.sup.3 is hydrogen, lower alkyl or phenyl; ##STR2## R.sup.

Abstract: Provided are methods of treating inflammation, arthritis and muscular dystrophy and preventing ischemia-induced cell damage employing certain phenol and benzamide compounds.

Abstract: Compositions containing 1.alpha.-hydroxyvitamin D homolog compounds in a suitable carrier and methods employing such compositions are disclosed for cosmetic uses in the treatment of various skin conditions such as lack of adequate skin firmness, wrinkles, dermal hydration and sebum secretion. Various formulations of the compositions including creams, lotions and ointments are disclosed for use topically, orally or parenterally in accordance with this invention.

Abstract: The present invention relates to new therapeutic uses of lipophilic extracts of Commiphora mukul, prepared from exudate of said plant, as well as the preparation of pure compounds or highly standardized fractions thereof as active ingredients. The extracts, the fractions thereof or the single pure active ingredients isolated therefrom proved to be useful in the treatment of inflammations, both of allergic origin and not, concerning skin and external mucosae, and in the symptomatic treatment of benign prostatic hypertrophy and in the resolutive treatment of acne.

Abstract: Synthetic oligopeptides having potent anti-inflammatory and phospholipase A.sub.2 inhibiting properties are described. A method of controlling inflammation of body tissue is also described.

Abstract: A benzonaphthalene compound has the formula ##STR1## wherein R.sub.1 represents ##STR2## or (ii) --CH.sub.2 OH; R.sub.6 represents ##STR3## or OR.sub.7 wherein R.sub.7 represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl or polyhydroxyalkyl, r' or r" represent hydrogen, lower alkyl, mono or polyhydroxyalkyl, aryl or a residue of an amino acid or a sugar, or together form a heterocycle; R.sub.2 represents hydrogen, alkyl having 1-15 carbon atoms, alkoxy having 1-4 carbon atoms or a cycloaliphatic radical; R.sub.3 represents hydrogen, hydroxy, alkyl having 1-4 carbon atoms, alkoxy having 1-10 carbon atoms, a cycloaliphatic radical, a thiocycloaliphatic radical or --O--Si(CH.sub.3).sub.2 --R.sub.8 wherein R.sub.8 represents lower alkyl; and R.sub.4 and R.sub.5 represent hydrogen, lower alkyl, hydroxy or lower acyloxy.This compound is useful in the topical and systemic treatment of dermatologic diseases and in the treatment of the degeneration of conjunctive tissues.